ECSP14030537A - Derivados de benzamida para la inhibición de la actividad de abl1, abl2 y bcr-abl1 - Google Patents
Derivados de benzamida para la inhibición de la actividad de abl1, abl2 y bcr-abl1Info
- Publication number
- ECSP14030537A ECSP14030537A ECIEPI201430537A ECPI201430537A ECSP14030537A EC SP14030537 A ECSP14030537 A EC SP14030537A EC IEPI201430537 A ECIEPI201430537 A EC IEPI201430537A EC PI201430537 A ECPI201430537 A EC PI201430537A EC SP14030537 A ECSP14030537 A EC SP14030537A
- Authority
- EC
- Ecuador
- Prior art keywords
- abl1
- bcr
- activity
- abl2
- inhibition
- Prior art date
Links
- 230000000694 effects Effects 0.000 title abstract 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical class NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 title 1
- 101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 title 1
- 101000823271 Homo sapiens Tyrosine-protein kinase ABL2 Proteins 0.000 title 1
- 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 title 1
- 102100022651 Tyrosine-protein kinase ABL2 Human genes 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/12—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by hydrolysis, i.e. solvolysis in general
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente invención se ref iere a los compuestos de la fórmula ( I ) : en donde Y, Y1 , R1 , R2, R3 y R4 se def inen en la Breve Descr ipción de la Invención; capaces de inhibi r la act ividad de BCR-ABL1 y los mutantes de los mismos. La invención proporciona además un proceso para la preparación de los compuestos de la invención, las preparaciones farmacéut icas que comprenden estos compuestos, y los métodos para ut i l izar tales compuestos en el t ratamiento de cánceres.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261644616P | 2012-05-09 | 2012-05-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP14030537A true ECSP14030537A (es) | 2015-09-30 |
Family
ID=48444372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECIEPI201430537A ECSP14030537A (es) | 2012-05-09 | 2014-12-08 | Derivados de benzamida para la inhibición de la actividad de abl1, abl2 y bcr-abl1 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20150087808A1 (es) |
| EP (1) | EP2847211A1 (es) |
| JP (3) | JP2015517481A (es) |
| KR (1) | KR20150006435A (es) |
| CN (2) | CN104284902A (es) |
| AR (1) | AR090964A1 (es) |
| AU (2) | AU2013257989A1 (es) |
| BR (1) | BR112014027648A2 (es) |
| CA (1) | CA2868940A1 (es) |
| CL (1) | CL2014003014A1 (es) |
| CO (1) | CO7141428A2 (es) |
| EA (1) | EA024903B1 (es) |
| EC (1) | ECSP14030537A (es) |
| HK (1) | HK1202555A1 (es) |
| IL (1) | IL235428A0 (es) |
| IN (1) | IN2014DN08483A (es) |
| MA (1) | MA20150231A1 (es) |
| MX (1) | MX2014013613A (es) |
| PE (1) | PE20142433A1 (es) |
| PH (1) | PH12014502499A1 (es) |
| SG (1) | SG11201406303XA (es) |
| TN (1) | TN2014000411A1 (es) |
| TW (1) | TW201350508A (es) |
| WO (1) | WO2013167703A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105693820A (zh) * | 2014-11-27 | 2016-06-22 | 武汉药明康德新药开发有限公司 | 一种降解环孢菌素a的方法 |
| JP7634933B2 (ja) | 2017-05-12 | 2025-02-25 | 中外製薬株式会社 | 環状有機化合物の製造方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT401177B (de) * | 1993-10-22 | 1996-07-25 | Biochemie Gmbh | Verfahren zur herstellung von 7-amino-3-cephem-4-carbonsäure-derivaten |
| USRE40987E1 (en) * | 1998-07-01 | 2009-11-17 | Debiopharm S.A. | Cyclosporin with improved activity profile |
| WO2000046239A1 (fr) * | 1999-02-05 | 2000-08-10 | Debiopharm S.A. | Derives de cyclosporine et procede de preparation desdits derives |
| DE60208180T2 (de) * | 2001-04-20 | 2006-08-17 | Debiopharm S.A. | Modifiziertes, als medikamentvorstufe anwendbares cyclosporin und dessen verwendung |
| DE60231570D1 (de) * | 2001-10-19 | 2009-04-23 | Isotechnika Inc | Synthese von Cyclosporinanalogen |
| TW200505946A (en) | 2003-04-08 | 2005-02-16 | Hoffmann La Roche | Process for preparation of cyclosporin a analog |
| PT1793844E (pt) | 2004-10-01 | 2011-03-10 | Debiopharm Sa | Utilização de [d-meala]3-[etval]4-csa para o tratamento de infecção causada pelo vírus da hepatite c |
| BRPI0517207A (pt) * | 2004-12-17 | 2008-09-30 | Isotechnika Inc | composto isolado, metabólito isolado de ciclo {{(e)- e (z)- (2s,3r,4r)-3-hidróxi-4-metil-2-(metilamino)-6,8-nonadien oil}-l-2-aminobutiril-n-metil-glicil-n-metil-l-leucil-l-v alil-n-metil-l-leucil-l-alanil-d-alanil-n-metil-l-leucil- n-metil-l-leucil-n-metil-l-valil} (isa247) e os sais e solvatos farmaceuticamente aceitáveis dos mesmos, método de preparação de metabólitos de isa247 in vitro, método de produção de um metabólito hidroxilado de isa247, metabólito hidroxilado isolado de isa247, metabólito hidroxilado isolado, método de produção de um metabólito de epóxido de isa247 in vitro, metabólito isolado de epóxido de isa247, metabólito isolado de epóxido, método de produção de um metabólito de diol de isa247 in vitro, metabólito de diol isolado de isa247, metabólito de diol isolado, método de produção de um metabólito de diol de isa247, método de produção de um metabólito de diol de isa247 e composição farmacêutica |
| RU2462262C2 (ru) | 2007-01-04 | 2012-09-27 | Дебиофарм С А | Неиммуносупрессорный циклоспорин для лечения врожденной миопатии ульриха |
| WO2009042892A1 (en) | 2007-09-26 | 2009-04-02 | Oregon Health & Science University | Cyclic undecapeptides and derivatives as multiple sclerosis therapies |
| US7910378B2 (en) * | 2007-12-14 | 2011-03-22 | Siemens Healthcare Diagnostics Inc. | Methods for detection of hydrophobic drugs |
| WO2009098533A1 (en) | 2008-02-08 | 2009-08-13 | Debiopharm Sa | Non -immunosuppressive cyclosporin for the treatment of muscular dystrophy |
| CA2741829A1 (en) | 2008-11-06 | 2010-05-14 | Debio Recherche Pharmaceutique S.A. | Cycloundecadepsipeptide compounds and use of said compounds as a medicament |
| CA2748389A1 (en) * | 2008-12-31 | 2010-07-08 | Scynexis, Inc. | Derivatives of cyclosporin a |
| EP2391376A4 (en) * | 2009-01-30 | 2012-08-01 | Enanta Pharm Inc | ANALOGUES OF CYCLOSPORIN FOR PREVENTING OR TREATING HEPATITIS C INFECTION |
| WO2012021796A2 (en) * | 2010-08-12 | 2012-02-16 | S&T Global, Inc. | Novel cyclosporin derivatives for the treatment and prevention of a viral infection |
-
2013
- 2013-05-07 AR ARP130101557A patent/AR090964A1/es unknown
- 2013-05-08 HK HK15102858.0A patent/HK1202555A1/xx unknown
- 2013-05-08 PE PE2014001983A patent/PE20142433A1/es not_active Application Discontinuation
- 2013-05-08 IN IN8483DEN2014 patent/IN2014DN08483A/en unknown
- 2013-05-08 SG SG11201406303XA patent/SG11201406303XA/en unknown
- 2013-05-08 EA EA201492036A patent/EA024903B1/ru not_active IP Right Cessation
- 2013-05-08 KR KR1020147031112A patent/KR20150006435A/ko not_active Withdrawn
- 2013-05-08 BR BR112014027648A patent/BR112014027648A2/pt not_active IP Right Cessation
- 2013-05-08 US US14/399,261 patent/US20150087808A1/en not_active Abandoned
- 2013-05-08 JP JP2015510823A patent/JP2015517481A/ja not_active Withdrawn
- 2013-05-08 WO PCT/EP2013/059672 patent/WO2013167703A1/en not_active Ceased
- 2013-05-08 EP EP13722740.1A patent/EP2847211A1/en not_active Withdrawn
- 2013-05-08 MX MX2014013613A patent/MX2014013613A/es unknown
- 2013-05-08 CN CN201380023760.8A patent/CN104284902A/zh active Pending
- 2013-05-08 CN CN201810575515.2A patent/CN108715606A/zh active Pending
- 2013-05-08 AU AU2013257989A patent/AU2013257989A1/en not_active Abandoned
- 2013-05-08 MA MA37498A patent/MA20150231A1/fr unknown
- 2013-05-08 CA CA2868940A patent/CA2868940A1/en not_active Abandoned
- 2013-05-08 TW TW102116414A patent/TW201350508A/zh unknown
-
2014
- 2014-09-30 TN TNP2014000411A patent/TN2014000411A1/fr unknown
- 2014-10-30 IL IL235428A patent/IL235428A0/en unknown
- 2014-11-07 CL CL2014003014A patent/CL2014003014A1/es unknown
- 2014-11-10 PH PH12014502499A patent/PH12014502499A1/en unknown
- 2014-11-10 CO CO14248207A patent/CO7141428A2/es unknown
- 2014-12-08 EC ECIEPI201430537A patent/ECSP14030537A/es unknown
-
2016
- 2016-06-30 US US15/198,152 patent/US9840534B2/en not_active Expired - Fee Related
- 2016-08-31 AU AU2016222370A patent/AU2016222370B2/en not_active Ceased
-
2017
- 2017-08-29 JP JP2017164867A patent/JP2018035154A/ja not_active Withdrawn
-
2019
- 2019-09-30 JP JP2019179311A patent/JP2020033349A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MA20150231A1 (fr) | 2015-07-31 |
| CL2014003014A1 (es) | 2015-03-06 |
| CN104284902A (zh) | 2015-01-14 |
| HK1202555A1 (en) | 2015-10-02 |
| IL235428A0 (en) | 2014-12-31 |
| US9840534B2 (en) | 2017-12-12 |
| EA024903B1 (ru) | 2016-10-31 |
| AR090964A1 (es) | 2014-12-17 |
| CO7141428A2 (es) | 2014-12-12 |
| EA201492036A1 (ru) | 2015-02-27 |
| PH12014502499A1 (en) | 2014-12-22 |
| AU2016222370A1 (en) | 2016-09-15 |
| PE20142433A1 (es) | 2015-02-02 |
| BR112014027648A2 (pt) | 2017-06-27 |
| EP2847211A1 (en) | 2015-03-18 |
| CA2868940A1 (en) | 2013-11-14 |
| JP2018035154A (ja) | 2018-03-08 |
| US20150087808A1 (en) | 2015-03-26 |
| CN108715606A (zh) | 2018-10-30 |
| JP2020033349A (ja) | 2020-03-05 |
| TN2014000411A1 (en) | 2015-12-21 |
| JP2015517481A (ja) | 2015-06-22 |
| KR20150006435A (ko) | 2015-01-16 |
| MX2014013613A (es) | 2015-02-12 |
| SG11201406303XA (en) | 2014-11-27 |
| AU2013257989A1 (en) | 2014-10-23 |
| US20160304554A1 (en) | 2016-10-20 |
| WO2013167703A1 (en) | 2013-11-14 |
| AU2016222370B2 (en) | 2017-10-05 |
| TW201350508A (zh) | 2013-12-16 |
| WO2013167703A9 (en) | 2014-11-20 |
| IN2014DN08483A (es) | 2015-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2014000256A (es) | Derivados de benzamida para la inhibición de la actividad de abl1, abl2 y bcr-abl1 | |
| BR112014027181A2 (pt) | derivados de benzamida para a inibição da atividade de abl1, abl2 e bcr-abl1 | |
| MX2021007432A (es) | Compuestos y composiciones para inhibir la actividad de shp2. | |
| MX357305B (es) | Compuestos y composiciones para inhibir la actividad de abl-1, abl-2, y bcr-abl1. | |
| BR112015021983A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
| NI201200184A (es) | Morfolinopirimidinas y su uso en terapia | |
| NI201600014A (es) | Compuestos y composiciones como inhibidores de la mek. | |
| EA201491362A1 (ru) | Анестезирующие соединения и способы их применения | |
| IN2014MN01754A (es) | ||
| MX2015009057A (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de cinasa pim. | |
| EA201590453A1 (ru) | Конденсированные бициклические производные сульфамоила и их применение в качестве лекарственных препаратов для лечения гепатита b | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| CR20130371A (es) | IMIDAZO[5,1-f][1,2,4]TRIAZINAS PARA EL TRATAMIENTO DE TRASTORNOS NEUROLÓGICOS | |
| NZ703162A (en) | Heterocyclic modulators of lipid synthesis | |
| IN2014MN02106A (es) | ||
| ECSP14013217A (es) | 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk. | |
| CU20150014A7 (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| BR112013018515A2 (pt) | derivados de pirrol tricíclico, processo para preparação e seu uso como inibidores da quinase | |
| EA201301319A1 (ru) | Производные пиридин-2(1н)-она, применимые в качестве лекарственных средств для лечения миелопролиферативных нарушений, отторжения трансплантата, иммунологически обусловленных и воспалительных заболеваний | |
| EA201500182A1 (ru) | 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ | |
| EA201370166A1 (ru) | Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы | |
| CO7280475A2 (es) | Derivados de azaindol que actuan como inhibidores de pi3k | |
| ECSP14030537A (es) | Derivados de benzamida para la inhibición de la actividad de abl1, abl2 y bcr-abl1 | |
| CU20100250A7 (es) | Compuestos pirazólicos 436 |